ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013
WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NAS: ARQL) today announced that it will report its financial results for the second quarter of 2013 on Tuesday, July 30, 2013 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.
Conference Call and Webcast
|Date:||Tuesday, July 30, 2013|
|Time:||9:00 a.m., Eastern Time|
Conference Call Numbers
|Domestic (toll free):||(877) 868-1831|
A replay of the conference call will be available beginning two hours after the completion of the call through August 1, 2013 and can be accessed by dialing toll-free 855-859-2056 and outside the U.S. 404-537-3406. The confirmation code for replayed calls is 19175389.
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company's pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621, designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to inhibit the RAF kinases. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
William B. Boni, 781-994-0300
VP, Investor Relations/
KEYWORDS: United States North America Massachusetts
The article ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.